Alnylam Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $1.77B | $645.4M |
| FY2018 | — | $1.30B | $420.1M |
| FY2019 | — | $1.44B | $547.2M |
| FY2020 | — | $1.02B | $496.6M |
| FY2021 | — | $588.2M | $820.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $1.77B | $645.4M |
| FY2018 | — | $1.30B | $420.1M |
| FY2019 | — | $1.44B | $547.2M |
| FY2020 | — | $1.02B | $496.6M |
| FY2021 | — | $588.2M | $820.0M |